Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update

AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update SAN DIEGO, November 12, 2026 -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results for

Event · Earnings
Original reporting
Published Nov 12, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AEMD
Bearish
high confidence
Mentioned
$AEMD
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AEMDBearishMed
01

Why it matters

The merger announcement introduces execution risk and potential dilution, while the Q2 results show a sharp rise in expenses and modest cash, suggesting near‑term financing pressure.

02

Market read

The new merger agreement and Q2 results provide fresh material for traders to assess AEMD's short‑term risk and potential long‑term upside.

03

What to watch

The contingent value rights (CVR) may provide future upside if the legacy business is monetized, which could mitigate current dilution concerns.

Relevance 7/10Novelty 8/10Timing: immediate filing today

Background

Aethlon Medical (Nasdaq: AEMD) is a clinical‑stage company focused on its Hemopurifier device. The filing includes Q2 financials and a merger plan with North Immunology.

Company-level read

Ticker impact

$AEMDBearishHigh confidence
Context

SEC 8‑K filing announces a definitive merger agreement with North Immunology and provides Q2 fiscal 2027 results.

Expected impact

likely downside as market prices in merger‑related dilution and higher expenses

Evidence & confidence

The merger is newly disclosed, carries execution risk, and the company reports a 77% rise in operating expenses and limited cash, suggesting near‑term weakness.

Market effects

Potential consolidation in the niche medical‑device/viral‑purification sector could affect peers developing similar technologies.

Limited to U.S. biotech investors; no broader regional effect.

Low global impact beyond specialty biotech space.

Counterpoint

If the merger succeeds, the combined entity could unlock value from the Hemopurifier platform, offering upside despite short‑term dilution.

Key entities

  • Aethlon Medical, Inc.

    Nasdaq‑listed clinical‑stage medical‑device firm.

  • North Immunology, Inc.

    Merger partner; will become the surviving entity.

Related articles

$AEMDMed

Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update

Aethlon Medical (AEMD) reported Q2 2027 results, including $6.5M in cash, $2.7M in operating expenses, and progress in a Phase 1 oncology study. The company announced a merger with North Immunology, with shareholders to receive contingent value rights. The merger may lead to workforce reductions and wind-down of legacy activities. The company remains operational and continues to evaluate resources.

$LSTAHighAI 9/10

Lisata and Aethlon close reverse merger deals

Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock deal with a $225M private placement, gaining access to Marea's cardioendocrine pipeline. Aethlon Medical merged with North Immunology in an all-stock deal with a $180M private placement, focusing on NOR-101 for atopic dermatitis. Both deals aim to advance pipelines and create value for shareholders.

$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

$AEMDHighAI 9/10

Medical Tech Stock Aethlon Medical, Inc. (Nasdaq: AEMD) Soars on Merger News

Aethlon Medical (AEMD) stock surged 393% after announcing a merger with North Immunology, a biotech developing treatments for immune and inflammatory diseases. The all-stock deal includes a $180M private placement and aims to advance NOR-101, a bispecific antibody for atopic dermatitis. The combined company will trade on Nasdaq under NRTX, with Aethlon shareholders owning 4.75% post-merger.